| Literature DB >> 34685496 |
Ahmed Ghallab1,2, Maiju Myllys1, Adrian Friebel3, Julia Duda4, Karolina Edlund1, Emina Halilbasic5, Mihael Vucur6, Zaynab Hobloss1, Lisa Brackhagen1, Brigitte Begher-Tibbe1, Reham Hassan1,2, Michael Burke7, Erhan Genc7, Lynn Johann Frohwein8, Ute Hofmann9, Christian H Holland10, Daniela González1, Magdalena Keller1, Abdel-Latif Seddek2, Tahany Abbas11, Elsayed S I Mohammed12, Andreas Teufel13, Timo Itzel13, Sarah Metzler14, Rosemarie Marchan1, Cristina Cadenas1, Carsten Watzl14, Michael A Nitsche15, Franziska Kappenberg4, Tom Luedde6, Thomas Longerich16, Jörg Rahnenführer4, Stefan Hoehme3, Michael Trauner5, Jan G Hengstler1.
Abstract
Mouse models of non-alcoholic fatty liver disease (NAFLD) are required to define therapeutic targets, but detailed time-resolved studies to establish a sequence of events are lacking. Here, we fed male C57Bl/6N mice a Western or standard diet over 48 weeks. Multiscale time-resolved characterization was performed using RNA-seq, histopathology, immunohistochemistry, intravital imaging, and blood chemistry; the results were compared to human disease. Acetaminophen toxicity and ammonia metabolism were additionally analyzed as functional readouts. We identified a sequence of eight key events: formation of lipid droplets; inflammatory foci; lipogranulomas; zonal reorganization; cell death and replacement proliferation; ductular reaction; fibrogenesis; and hepatocellular cancer. Functional changes included resistance to acetaminophen and altered nitrogen metabolism. The transcriptomic landscape was characterized by two large clusters of monotonously increasing or decreasing genes, and a smaller number of 'rest-and-jump genes' that initially remained unaltered but became differentially expressed only at week 12 or later. Approximately 30% of the genes altered in human NAFLD are also altered in the present mouse model and an increasing overlap with genes altered in human HCC occurred at weeks 30-48. In conclusion, the observed sequence of events recapitulates many features of human disease and offers a basis for the identification of therapeutic targets.Entities:
Keywords: NASH; intravital imaging; non-invasive imaging; transcriptomics
Mesh:
Year: 2021 PMID: 34685496 PMCID: PMC8533774 DOI: 10.3390/cells10102516
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Materials and resources.
| Reagent or Resource | Source | Identifier |
|---|---|---|
|
| ||
| Anti-liver arginase1 antibody, rabbit | Abcam, Cambridge, UK | ab203490 |
| Anti-arginase1 antibody, goat | Novus Biologicals, Littleton, USA | NB100-59740 |
| Bodipy 495/503 | Thermo Fisher Scientific, Waltham, USA | D3922 |
| Anti-mouse CD45 antibody, rat | BD Bioscience, Heidelberg, Germany | 550539 |
| Anti-human CD68 monoclonal antibody, mouse | DakoCytomation A/S, Glostrup, Denmark | M0876 |
| Anti-K18 polyclonal antibody, rabbit | Proteintech, Manchester, UK | 10830-1-AP |
| Recombinant anti-K19 antibody, rabbit | Abcam, Cambridge, UK | ab52625 |
| Recombinant anti-CPS1 monoclonal antibody, rabbit | Abcam, Cambridge, UK | ab129076 |
| Anti-Cyp2e1 antibody, rabbit | Sigma-Aldrich, St. Louis, USA | HPA009128 |
| Anti-mouse desmin antibody, rabbit | Thermo Fisher Scientific, Waltham, USA | RB -9014-P0 |
| Anti-mouse F4/80 monoclonal antibody, rat | Bio-Rad, Hercules, USA | MCA497 |
| Anti-GS polyclonal antibody, rabbit | Sigma, St. Louis, USA | G2781 |
| Anti-GS polyclonal antibody, rabbit | Sigma, St. Louis, USA | G2781 |
| Anti-Ki67 antibody, rabbit | Cell Signaling Technology, Danvers, USA | D3B5 |
| Anti- cl. Caspase 3 (rabbit) monoclonal | Cell Signaling Technology, Danvers, USA | 9661S |
|
| ||
| Hoechst 33258 | Thermo Fisher Scientific, Waltham, USA | H21491 |
| Tetramethylrhodamine ethyl ester (TMRE) | Thermo Fisher Scientific, Waltham, USA | T669 |
| Cholyl-lysyl-fluorescein (CLF) | Corning | 451041 |
| PE-F4/80 antibody | Thermo Scientific (eBioscience) , Waltham, USA | 12-4801-82 |
| Rhodamine 123 | Thermo Fisher Scientific, Waltham, USA | R302 |
| Bodipy 493/503 | Thermo Fisher Scientific, Waltham, USA | D3922 |
|
| ||
| ssniff R/M-H, 10 mm standard diet | Ssniff, Soest, Germany | V1534-000 |
| Western-style diet | Research Diets, New Brunswick, USA | D09100301 |
|
| ||
| Acetaminophen | Sigma-Aldrich, St. Louis, USA | A7085-500G |
| LPS | Sigma-Aldrich, St. Louis, USA | 297-473-0 |
| Gadoxetic acid (Primovist) 0.25 mmol/mL | Bayer, Wuppertal, Germany | KT07561 |
|
| ||
| DeadEnd™ Fluorometric TUNEL System | Promega, Walldorf, Germany | G3250 |
| Bluing Reagent | Roche, Mannheim, Germany | 05 266 769 001 |
| Discovery yellow Kit (RUO) | Roche, Mannheim, Germany | 07 698 445 001 |
| Discovery Teal HRP Kit (RUO) | Roche, Mannheim, Germany | 8254338001 |
| Chromo Map DAB | Roche, Mannheim, Germany | 05 266 645 001 |
| Piccolo general chemistry 13 | Hitado, Möhnesee, Germany | AB-114-400-0029 |
| Picrosirius Red Stain Kit | Polysciences Polysciences Inc., Warrington, USA | 24901 |
| RNeasy Mini Kit | Qiagen, Hilden, Germany | 74116 |
| RNase-Free DNase Set | Qiagen, Hilden, Germany | 79254 |
| RNA BR Assay Kit | Thermo Fisher Scientific, Waltham, USA | Q10210 |
| RNA 6000 Nano Kit | Agilent Technologies, CA, USA | 5067-1511 |
| Qubit 1X dsDNA HS Assay Kit | Thermo Fisher Scientific, Waltham, USA | Q33230 |
| DNA 1000 Kit | Agilent Technologies, CA, USA | 5067-1504 |
|
| ||
| Anti- MLKL | Biorbyt LLC, Cambridge, UK | orb32399 |
| Anti- cleaved-Caspase-3 | Cell Signaling Technology, Danvers, USA | 9661S |
| Anti- GAPDH | AbD Serotec, Hercules, USA | MCA 4739 |
|
| ||
| GraphPad Prism 9.1 Software | GraphPad, San Diego, USA | NA |
| Zen | Carl-Zeiss, Jena, Germany | NA |
| ImageJ 1.8.0_172 | NA | |
|
| ||
| LSM MP7 two-photon microscope | Zeiss, Jena, Germany | NA |
| Axio Scan.Z1 | Zeiss, Jena, Germany | N/A |
| Confocal Laser Scanning Microscope FLUOVIEW FV1000 | Olympus, Hamburg, Germany | N/A |
| DISCOVERY ULTRA Automated Slide Preparation System | Roche, Mannheim, Germany | N/A |
| Piccolo Xpress® chemistry analyzer | Abaxis, Union City, USA | N/A |
| PocketChem BA PA-4140 ammonia meter | Arkray.inc, Amstelveen, The Netherlands | N/A |
| 3Tesla MRI scanner | Prisma, Siemens Healthineers, Erlangen, Germany | |
Ingredients of the used Western-style diet.
| Ingredient | Grams | Kcal | % |
|---|---|---|---|
| Casein, 80 mesh | 200 | 800 | 22.12 |
| 3 | 12 | 0.33 | |
| Maltodextrin 10 | 100 | 400 | 11.06 |
| Fructose | 200 | 800 | 22.12 |
| Sucrose | 96 | 384 | 10.62 |
| Cellulose, BW200 | 50 | 0 | 5.53 |
| Soybean oil | 25 | 225 | 2.77 |
| Primex shortening | 135 | 1215 | 14.93 |
| Lard | 20 | 180 | 2.21 |
| Mineral Mix S10026 | 10 | 0 | 1.11 |
| Dicalcium phosphate | 13 | 0 | 1.44 |
| Calcium carbonate | 5.5 | 0 | 0.61 |
| Potassium citrate, 1 H2O | 16.5 | 0 | 1.83 |
| Vitamin Mix V10001 | 10 | 40 | 1.11 |
| Choline bitartrate | 2 | 0 | 0.22 |
| Cholesterol | 18 | 0 | 1.99 |
| FD&C Yellow dye | 0.05 | 0 | 0.006 |
| Total | 904.05 | 4056 | 100 |
| Total protein | 20 Kcal % | 22 | |
| Total carbohydrate | 40 Kcal % | 45 | |
| Total fat | 40 Kcal % | 20 |
Overview of the number of analyzed mice per experimental condition.
| Diet | Feeding Time (Weeks) | Number of Mice Analyzed | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Liver/Body Weight, RNA-seq, Histology, IHC | HCC | MRI | Intravital Imaging | Nitrogen | APAP | Necroptosis Analysis | LPS | |||
| + | − | |||||||||
|
| 3 | 5 | 0 | 5 | 3 | 4 | ||||
| 6 | 5 | 0 | 5 | 4 | ||||||
| 9 | 3 | - | ||||||||
| 12 | 5 | 0 | 5 | 4 | ||||||
| 18 | 5 | 0 | 5 | 4 | ||||||
| 24 | 5 | 0 | 5 | 6 | 4 | |||||
| 30 | 5 | 4 | 1 | 4 | ||||||
| 32 | 3 | |||||||||
| 36 | 5 | 1 | 4 | 4 | ||||||
| 42 | 4 | 5 | 4 | 3 | ||||||
| 48 | 8 | 6 | 2 | 4 | 3 | |||||
| ~50 | 7 | |||||||||
|
| 3 | 7 | 0 | 7 | 3 | 4 | ||||
| 6 | 5 | 0 | 5 | |||||||
| 30 | 5 | 0 | 5 | |||||||
| 36 | 7 | 0 | 7 | 4 | ||||||
| 42 | 3 | 0 | 3 | 4 | ||||||
| 48 | 5 | 0 | 5 | 4 | ||||||
| ~50 | 7 | |||||||||
Fluorescent markers and functional dyes used for intravital imaging.
| Dye/Marker | Marker for | Dose | Vehicle | Two-Photon Excitation Range (nm) |
|---|---|---|---|---|
| Hoechst 33258 | Nuclei | 5 | PBS | 700–800 |
| TMRE | Lobular zonation; mitochondrial membrane potential | 0.96 | Methanol/PBS (1:1) | 780–820 |
| Rhodamine123 | 0.8 | Methanol/PBS (1:1) | 720–820 | |
| Cholyl-lysyl-fluorescein | Bile acid analogue | 1 | PBS | 740–820 |
| Bodipy 493/503 | Lipids | 0.004 | DMSO | 900–940 |
| PE-F4/80 antibody | Macrophages | 0.06 | PBS | 720–760 |
Figure 1Lipid droplet accumulation and tumor development after Western diet feeding. (A) Experimental schedule indicating the number of weeks mice were on a SD or WD prior to analysis; green triangles: time periods with SD controls (details: Table 3). (B) Macroscopic appearance of the livers of mice on SD (week 3) and WD over 48 weeks. (C) Body weight and liver-to-body weight ratio. (D) Lipid droplet (LD) formation in H&E-stained liver tissue sections of mice fed a WD over 48 weeks; scale bars: 50 µm. (E) Zonation of LD formation. LD appear white, the periportal/midzonal regions are green due to immunostaining for arginase1 (Arg.); blue represents nuclear staining by DAPI; CV: central vein; PV: portal vein; scale bars: 50 µm. (F) Intravital visualization of LD using Bodipy (green). Differentiation of the periportal (PP) and pericentral (PC) lobular zones was achieved using the mitochondrial dye, TMRE, that leads to a stronger signal in the PP than the PC zone; scale bar: 50 µm (see also Videos S1 and S2). (G) Quantification of LD in relation to lobular zonation. Data in C and G represent the mean and standard error of 4–7 mice per time point. **: p < 0.01; ***: p < 0.001 compared to SD week 3, Dunnett’s (C) or Sidak’s (G) multiple comparisons tests; data of individual mice are illustrated by dots; SD: standard diet; WD: Western diet. (H) Immunostaining of a GS positive (upper panel; scale bars: 1 mm for whole slide scans and 100 µm for the closeup) and a GS negative (lower panel; scale bars: 2 mm for whole slide scans and 100 µm for the closeup tumor nodule from 48-week WD-fed mice for the hepatocyte marker K18, the periportal/midzonal marker arginase1, and the proliferation marker Ki67. (I) Stills from MRI analysis of a SD-fed mouse, week 48, before (0 min), as well as 1 and 30 min after injection of the contrast agent gadoxetic acid; GB: gallbladder. (J) Quantification of the gadoxetic acid-associated signal in the regions of interest indicated in I. (K) Visualization of hepatocellular carcinoma (HCC) that appears as a hypodense region (red arrow) in the liver of a WD-fed mouse at week 48 in comparison to the gross pathology of the same mouse. (L) Mean intensity of the MRI signal of gadoxetic acid in the tumor and non-tumor region of the liver after injection of gadoxetic acid.
Antibodies/dyes used for immunohistochemistry analysis.
| Target | Primary Antibodies | Secondary Antibodies | ||
|---|---|---|---|---|
| Antibody | Dilution | Antibody | Dilution | |
| Lipids | Bodipy 495/503 | 2 µg/mL | - | - |
| Arginase1 | Anti-arginase1 antibody, goat | 1:100 | Cy™5-conjugated AffiniPure donkey anti-goat IgG (H + L) | 1:200 |
| Anti-liver arginase1 antibody, rabbit | 1:2000 | Ultra-Map anti-rabbit HRP | Automatic | |
| Ultra-Map anti-rabbit alkaline phosphatase | ||||
| Leukocyte common antigen | Anti-mouse CD45 antibody, rat | 1:400 | Ultra-Map anti-rat HRP | |
| Macrophages, human | Anti-human CD68 monoclonal antibody, mouse | 1:500 | Ultra-Map anti-mouse HRP | |
| Cytoskeleton | Anti-K18 polyclonal antibody, rabbit | 1:400 | Ultra-Map anti-rabbit HRP | |
| Cholangiocyte, mouse | Recombinant anti-K19 antibody, rabbit | 1:500 | Ultra-Map anti-rabbit HRP | |
| Cholangiocyte, human | Recombinant anti-K19 antibody, rabbit | 1:2000 | Ultra-Map anti-rabbit HRP | |
| Carbamoyl-Phosphate Synthase1 | Recombinant anti-CPS1 monoclonal antibody, rabbit | 1:500 | Ultra-Map anti-rabbit HRP | |
| Cyp2e1 | Anti-Cyp2e1 antibody, rabbit | 1:100 | Ultra-Map anti-rabbit HRP | |
| Ultra-Map anti-rabbit alkaline phosphatase | ||||
| Hepatic stellate cells | Anti-mouse desmin antibody, rabbit | 1:400 | Ultra-Map anti-rabbit HRP | |
| Macrophages, mouse | Anti-mouse F4/80 monoclonal antibody, rat | 1:50 | Ultra-Map anti-rat HRP | |
| Glutamine synthetase, mouse | Anti-GS polyclonal antibody, rabbit | 1:15,000 | Ultra-Map anti-rabbit HRP | |
| Apoptosis | Anti- cl. Caspase 3 monoclonal antibody, rabbit | 1:500 | Ultra-Map anti-rabbit HRP | |
| Glutamine synthetase, human | Anti-GS polyclonal antibody, rabbit | 1:5000 | Ultra-Map anti-rabbit HRP | |
| Cell proliferation antigen | Anti-Ki-67 antibody, rabbit | 1:100 | Ultra-Map anti-rabbit HRP | |
Figure 2Time-resolved RNAseq analysis. (A) Principal component (PC) analysis of all WD- (blue) and SD- (red) fed mice. Numbers in the panel indicate weeks on the WD or SD feeding. (B) Numbers of differentially expressed genes (DEGs) compared to SD week 3; adj p < 0.01; abs(log2 fold change) ≥ log2 (1.5). The light blue and light green color indicate DEGs that are differentially expressed in the WD and SD for the time periods with available SD controls (weeks 3, 6, 30, 36, 42, 48). (C) Left: k-means clustering of the 1000 genes with highest variability. In parentheses: numbers of genes making up the individual clusters. Right: 10 most enriched gene ontology (GO)-groups of each cluster. Count: number of DEGs in each GO-group and fdr-adjusted p-value; only GO-groups with at least three DEGs were included. (D) Examples of rest-and-jump genes (RJG). (E) Similarity of DEGs for the individual WD feeding periods compared to human NAFLD, hepatocellular carcinoma (HCC), hepatitis C virus infected liver tissue (HCV), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC) for up (∆) and down (•) regulated genes. (See also gene lists in Datasheet S1.)
Figure 3Formation of lipogranulomas (‘macrophage crowns’) after Western diet feeding. (A) Visualization of inflammatory foci by CD45 immunostaining. (B) Visualization of lipogranulomas (arrows) by immunostaining of CD45 and F4/80, and their lobular zonation by co-staining with the pericentral marker Cyp2e1; an overview image of WD week 36 is shown in (C). (D) Quantification of lipogranulomas’ density and zonation on whole slide scans in relation to the lobular zone; data represent the mean and standard error of 3–7 mice per time point. **: p < 0.01; ***: p < 0.001 compared to SD week 3. Unpaired t test; data of individual mice are illustrated by dots; SD: standard diet; WD: Western diet. (E) Intravital imaging of livers of WD-fed mice after intravenous injection of a fluorophore-coupled F4/80 antibody (red), the mitochondrial membrane potential marker Rhodamine123 (R123), and Hoechst for nuclear staining. The red arrows indicate Kupffer cells, the white circle shows a vital steatotic hepatocyte with mitochondrial and nuclear structures surrounded by F4/80 positive macrophages, and the pink circle indicates a lipid droplet enclosed by macrophages without discernible mitochondria or nuclear signal. (F) Intravital imaging of lipid droplets visualized by Bodipy; the yellow arrows indicate macrophages surrounding a lipid droplet. (See also Videos S3 and S4). Scale bars: 50 µm (A,B,E,F) and 200 µm (C).
Figure 4Cell death during NASH progression. (A) TUNEL and Ki67 staining in liver sections of SD- (3 week) and WD-fed mice. (B) Liver enzyme activities (ALT and AST) in the heart blood of mice fed a SD or WD. (C) Examples of ballooning (arrows) and Mallory–Denk bodies (arrowhead, MDB) in H&E-stained liver tissue sections. (D) Visualization of ballooning and MDB by K18 immunostaining. (E,F) Representative image of Western blot with accompanying quantification of the necroptosis marker MLKL and the apoptosis marker cleaved caspase-3 in livers of SD- and WD-fed mice over time. (G) Cleaved caspase3 immunostaining at different time intervals after WD feeding; LPS: lipopolysaccharide. Data in B and F are means and standard error of 4–5 mice per time point. *: p < 0.05; **: p < 0.01; ***: p < 0.001 compared to SD week 3, Dunnett’s multiple comparisons (B) or unpaired t (F) tests; data of individual mice are illustrated by dots; SD: standard diet; WD: Western diet. Scale bars: 50 µm (A,G) and 10 µm (C,D).
Figure 5Development of bile-draining ductular reaction during NAFLD progression. (A) Immunostaining of the cholangiocyte marker K19 in liver sections of mice on SD (3 week) or WD over time. (B) Quantification of the K19 positive area. (C) ALP levels in blood of mice on SD or WD. (D) Intravital imaging after intravenous injection of the bile acid analogue CLF (green). Yellow arrows indicate ductular structures. Data in B and C represent mean and standard errors of 3–8 mice per time point. *: p < 0.05; **: p < 0.01; ***: p < 0.001 compared to SD week 3, Dunnett’s multiple comparisons test; data of individual mice are illustrated by dots; SD: standard diet; WD: Western diet; ALP: alkaline phosphatase; CLF: cholyl-lysyl-fluorescein. Scale bars 50 µm (A) and 100 µm (D).
Figure 6Fibrosis progression after Western diet feeding. (A) Staining of SD- or WD-fed mouse liver sections with desmin (scale bars: 50 µm), Sirius red, and GS (scale bars: 100 µm). Of note, GS expression expanded at week 36. In addition, central veins became localized to delicate fibrotic septa thus forming initial portal-central bridges indicating architectural distortion, which progressed until week 48. (B) Quantification of the desmin and Sirius red positive areas. Data represent mean and standard errors of 4–8 mice per time point. *: p < 0.05; **: p < 0.01; ***: p < 0.001 compared to SD week 3, Sidak’s multiple comparisons test; data of individual mice are illustrated by dots; SD: standard diet; WD: Western diet. (C) Whole slide scan (scale bar: 1000 µm) of a Sirius red-stained liver section from 48-week WD-fed mouse, with enlarged inset (scale bar: 30 µm) to show detail. (D) MRI analysis of the morphology, fat content, and hepatocyte uptake capacity after 48 weeks of SD and WD. (E,F) Quantification of the MRI signals representing fat content and hepatocyte uptake capacity. Data in E and F were acquired from three mice per time point; ***: p < 0.001 compared to SD, unpaired t test.
Figure 7Lobular reorganization of metabolizing enzymes and functional consequences. (A) Reorganization of the pericentral enzymes Cyp2e1 and GS and the periportal/midzonal enzyme arginase1 in liver of WD-fed mice. (B) Decrease in Cyp2e1 (pericentral) and the arginase1 (periportal/midzonal) lobular regions and increase of the pericentral GS positive zone after WD feeding. (C) Quantification of the Cyp2e1, arginase1, and GS positive lobular areas in whole slide scans; data represent mean and standard errors of 3–8 mice per time point. *: p < 0.05; ***: p < 0.001 compared to SD week 3, Sidak’s multiple comparisons test; data of individual mice are illustrated by dots. (D,E) Hepatotoxicity of 300 mg/kg APAP in mice fed a SD or a WD for ~50 weeks as evidenced by H&E staining (D) and liver enzymes in blood (E); data represent mean and standard error of 3–4 mice per group. *: p < 0.05; **: p < 0.01 compared to SD, Tukey’s multiple comparisons test; data of individual mice are illustrated by dots. (F–H) Functional consequences of WD feeding (42 weeks) on ammonia (F), glutamine (G), urea and arginine (H) blood concentrations; data represent mean and standard error of 3–4 mice per group. **: p < 0.01; ***: p < 0.001 compared to SD, Sidak’s multiple comparisons test; data of individual mice are illustrated by dots. SD: standard diet; WD: Western diet; GS: glutamine synthetase; ALT: alanine transaminase. Scale bars: 100 µm.
Figure 8Comparison of the key features identified in the Western diet mice to NAFLD patients. (A) H&E staining (scale bars: 100 µm), lipogranulomas (CD68; scale bars: 50 µm) as identified with arrows, ductular reaction (K19; scale bars: 50 µm), and Sirius red staining (SR; scale bars: 100 µm) in NAFLD patients of all fibrosis stages (F0–F4). (B) Hepatocellular ballooning (arrows) and Mallory–Denk bodies (arrowheads, MDB) in F2–F4 patients; scale bars: 10 µm. (C) Reduced Cyp2e1 expression in F3 and F4 patients. Note, the lobular reorganization as highlighted by patchy periportal Cyp2e1 expression in F4 patients; scale bars: 100 µm. (D) Increase an abnormal periseptal localization of glutamine synthetase (GS) expression and decrease in carbamoyl-phosphate synthase 1 (CPS1) in NAFLD liver tissue with advanced fibrosis; scale bars: 100 µm. Abbreviations: CV, central vein; PV, portal vein; F3: fibrosis stage 3; F4: fibrosis stage 4.
Similarities and differences of the present NAFLD mouse model and human NAFLD, concerning the key features analyzed in the present study.
| Similarities | Differences |
|---|---|
|
➢ Macrovesicular steatosis ➢ Zonal reorganization: ➢ Reduction of the periportal/midzonal zone expressing urea cycle enzymes ➢ Increase of the GS positive pericentral zone ➢ Decrease of the Cyp2e1 positive pericentral zone ➢ Lipogranulomas ➢ Hepatocyte ballooning ➢ Ductular reaction ➢ Pericellular fibrosis ➢ Hepatocellular cancer (HCC) |
➢ Zonation of lipid droplets and fibrosis: midzonal/periportal in mice; pericentral in adult humans ➢ Rate of HCC formation is higher in mice than humans ➢ Only ~30% of the genes altered in human NAFLD are also differentially expressed in the present mouse model ➢ Hepatocyte ballooning: late during disease progression in mice; early during disease progression in humans |